Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Melanoma 10Leukemia, Myeloid, Acute 8Neoplasm Metastasis 7Carcinoma, Renal Cell 7Myelodysplastic Syndromes 6Leukemia, Lymphocytic, Chronic, B-Cell 5Hematologic Neoplasms 5Prostatic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Pancreatic Neoplasms 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Triple Negative Breast Neoplasms 3Ovarian Neoplasms 3Myeloproliferative Disorders 3Lung Neoplasms 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Hodgkin Disease 3Clear-cell metastatic renal cell carcinoma 3Carcinoma, Non-Small-Cell Lung 3Burkitt Lymphoma 3Breast Neoplasms 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Neuroblastoma 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2

Interventions

Cisplatin 7Oxaliplatin 5Paclitaxel 4Fluorouracil 4Carboplatin 4Albumin-Bound Paclitaxel 4Taxes 3Mitomycin 3130-nm albumin-bound paclitaxel 3Nivolumab 2Leucovorin 2Doxorubicin 2veliparib 1tremelimumab 1talimogene laherparepvec 1soluble LAG-3 protein, human 1sodium thiosulfate 1pembrolizumab 1nintedanib 1irinotecan sucrosofate 1durvalumab 1dehydroftorafur 1cc-486 1avelumab 1Trastuzumab 1Semaxinib 1Radiotherapy 1Radiation 1Platinum 1Pharmacogenomic Variants 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Peritoneal Neoplasms × CTLA-4 Antigen × Clear all
NCT03508570 2025-05-22

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

M.D. Anderson Cancer Center

Phase 1 Completed
26 enrolled
Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡